A3P Biomedical has developed Stockholm3, a blood-based test designed for the early detection of prostate cancer. The test combines protein and genetic markers with clinical data in an algorithm that, according to the company, finds twice as many prostate cancer cases requiring treatment as the current industry standard PSA, while also reducing unnecessary biopsies by half. The test was developed by researchers at Karolinska Institutet and has been validated in studies with a total of over 75 men.
A total of SEK 750 million has been invested in the development, where Flerie Invest been one of the pieces of the puzzle. The company entered A3P 2022 in connection with a directed issue of a total of SEK 400 million, where it turned a blind eye to investors who Stena Line, Thomas von Koch, Christian Kinch and The Baltic Sea Foundation.
– It is promising that the Stockholm3 test has already replaced PSA at leading Nordic prostate cancer clinics, while at the same time being cost-effective for the broader healthcare system throughout Europe and the US, said Flerie Invests Thomas Eldered in a comment in connection with the entry.
Targeting development companies
During the journey, A3P has launched Stockholm3 in the USA, Switzerland and Germany, among other things, and now that it has established itself properly commercially, it is time for the development-focused Flerie to get off the train.
– After having contributed as active owners during the initial phase of A3P Biomedical's commercial development, we see that now is the right time to divest our holding in the company, says Flerie's CEO Ted FjällmanIt is clear that A3P Biomedical has a bright future ahead of it, but this opportunity to divest means that we can prioritize our focus areas of drug development and pharmaceutical services. This is in line with our strategy to continuously optimize the structure of our investment portfolio while providing our companies with the best conditions for long-term success.
With the withdrawal, Flerie's portfolio now consists of 28 companies. This week, the investment company released its monthly net asset value report, which showed that the net asset value amounts to just over 4 billion kronor, equivalent to 52,05 kronor per share. This can be compared to the share, which is currently trading at around 44 kronor.